Navigation Links
Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Date:9/24/2007

ANN ARBOR, Mich. Sept. 24 /PRNewswire/ -- Velcura Therapeutics, Inc., a biotechnology company developing therapies for bone disease, met with the U.S. Food and Drug Administration (FDA) Sept. 20 to clarify details for the early clinical development of VEL-0230, a drug developed to treat bone disease. The focus of the Pre-Investigational New Drug Application (IND) meeting was to obtain feedback from the FDA's Division of Oncology Drug Products about Velcura's completed preclinical studies, as well as Velcura's near-term clinical development plans for VEL-0230. VEL-0230 is a new chemical entity that has dual-acting properties that both stimulates bone formation and inhibits loss. The company, a 2007 Michigan 50 Companies to Watch award winner, plans to initiate clinical trials in 2008 for the use of this drug as a treatment for Multiple Myeloma, a blood cancer associated with profound bone loss.

Michael W. Long, PhD, President and Chief Executive Officer of Velcura, said, "We appreciate the thoughtful, comprehensive and responsive feedback we received in our pre-IND meeting with the FDA. This clear regulatory advice and direction will greatly assist our IND application planned for late 2007. Our laboratory investigations, in vivo animal models, and extensive non- clinical toxicology evaluations demonstrate that VEL-0230 is a safe and effective molecule. Its dual-action bone properties make it an ideal therapy for multiple bone diseases," Dr. Long added.

VEL-0230 is being studied preclinically for the treatment of diseases involving bone mineral disorders such as bone loss related to multiple myeloma, osteoporosis, bone metastases, and rheumatoid arthritis. Given VEL- 0230's promotion of bone formation, inhibition of bone loss and reduction of calcium levels, Velcura has chosen Myeloma as its lead indication, as the bone fragility, bone pain, high calcium levels and eventual kidney involvement present serious medical and quality of life issues to aff
'/>"/>

SOURCE Velcura Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
11. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/6/2009)....Y., Jan. 6 In recent controlled s...ty of Memphis , scientists found that the patented... first and only proven ingredient to increase leve...asing blood nitrate/nitrate (NOx) in human subject...nables an increase in blood flow to the skeletal m...
(Date:1/6/2009)...PANY, N.J., Jan. 6 Pacira Pharmace...ical company, announced today that enrollment,has...ials to evaluate the,safety and efficacy of a sin...(DepoBupivacaine) for prolonged postoperative anal...hoidectomy and in total knee,arthroplasty (TKA) a...
(Date:1/5/2009)...SE, Calif., Jan. 5 Women undergoin...ne medication to help support early,pregnancy, bu...his medication,can be painful for patients. Form...administered by subcutaneous injection or vaginal ... patient tolerance. , With patient well-bei...
(Date:12/27/2008)...S, Bermuda, Dec. 23 Warn...day that one of its subsidiaries and Mayne Pharma ... Hospira, Inc., have filed lawsuits against each o...Mylan Pharmaceuticals Inc. ("Mylan") and Impax Lab...or the District of New Jersey for infringement of ...
Breaking Medicine Technology:US Testing Proves Glyc'n Go(TM) Increases NO in the Blood Stream 2Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 2Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 3Fertility Physicians of Northern California Researchers Test New Forms of Progesterone Medication for Luteal Support During IVF 2Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 2Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 3NKTR 118 Shows Substantial Oral Bioavailability and Extended Half Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 1995 1NKTR 118 Shows Substantial Oral Bioavailability and Extended Half Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 1995 2NKTR 118 Shows Substantial Oral Bioavailability and Extended Half Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 1995 3NKTR 118 Shows Substantial Oral Bioavailability and Extended Half Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 1995 4NKTR 118 Shows Substantial Oral Bioavailability and Extended Half Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 1995 5NKTR 118 Shows Substantial Oral Bioavailability and Extended Half Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 1995 6UC San Diego researchers target tumors with tiny nanoworms 18615 1UC San Diego researchers target tumors with tiny nanoworms 18615 2UC San Diego researchers target tumors with tiny nanoworms 18615 3Linkwell Corporation Begins Training and Licensing Beijing Olympics Disinfection Teams 18614 1Linkwell Corporation Begins Training and Licensing Beijing Olympics Disinfection Teams 18614 2Linkwell Corporation Begins Training and Licensing Beijing Olympics Disinfection Teams 18614 3Linkwell Corporation Begins Training and Licensing Beijing Olympics Disinfection Teams 18614 4Catholic Charities Calls for Increased Support of Mothers in Need 3A 18612 1Catholic Charities Calls for Increased Support of Mothers in Need 3A 18612 2
...ed by FDA for long-term maintenance,treatment of C...bulized formoterol fumarate provides improved lung...anced patient quality of,life, and positive safety...e/ -- Data presented at the,International Conferen...ate that Perforomist (formoterol fumarate) Inhalat...
...s Blood Pressure in Obese and,Non-Obese Hypertensi...stCall/ -- Forest,Laboratories, Inc. today present... pooled analysis of nebivolol, a selective beta,1-...er review by,the U.S. Food and Drug Administration...m the two clinical studies show that,nebivolol dem...
Other Medicine Technology:Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 2Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 3Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 4Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 5Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 6Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 7Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy 2Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy 3Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy 4
(Date:1/8/2009)...embly Member Tom Torlakson Introduces AB 89 , ,.../ -- Today, Lung Cancer Alliance-California (LCA...son (D-11th District) for his continued leadership...lung cancer research. For the third consecutive y...rch is being considered in the California Legislat...
(Date:1/8/2009)...ered bad cholesterol more effectively than Zocor ,...After nearly a year of review, U.S. health officia... use of the controversial cholesterol-lowering dru...ion said there was no significant difference in ca...orin and patients taking the drug Zocor. , But,...
(Date:1/8/2009)...d Acquisition in 2009 Continues Growth Trend , ,...tCall/ -- IPC The Hospitalist Company, Inc. (Nasda...ian group practice company, announced today that i... Acute Care Consultants, Inc. (MACC) in St. Louis,...pansion in the St. Louis market, where IPC has est...
(Date:1/8/2009)...d when assessing traditional risk factors, experts...s) -- Two molecular signs -- or "biomarkers" -- of...trying to assess a person,s risk of stroke, new re...w risk, adding these markers does not change thing... cardiologist at the Methodist DeBakey Heart &...
Breaking Medicine News(10 mins):Health News:Lung Cancer Alliance Applauds New Legislation Funding Lung Cancer Research 2Health News:FDA Backs Cholesterol Drug Vytorin 2Health News:IPC The Hospitalist Company Acquires Missouri Practice Group 2Health News:Inflammation Markers May Help Predict Stroke Risk 2Health News:Inflammation Markers May Help Predict Stroke Risk 3
...o a new study shows that women with a specific ge...esterol when they take oestrogen.// Previous resea...) might protect women from heart disease. Now doct...ed a strong genetic influence in how a woman's cho...
...an psychiatrist has discovered that treating patie...lusions and halucinations.// Although antipsychoti...any people still suffer these. But researchers ha...rogen can help protect against schizophrenia, beca...
...o study in University of Texas, a novel blood test...ing a possible new way to predict who might get Al...icine in St. Louis said it is unclear whether a si..., but the findings in the animal studies appeared ...
...d Drug Administration announced that Vioxx - Merck...mation on its label. The FDA said that Merck can c...ations// than one older non-steroidal anti-inflamm...at the Vioxx label must mention that it might be l...
Other Medicine News:Health News:Blood test may aid foretell Alzheimer's 2
...ct Complete® is a scientifically advanced nutr...ion for macular and full body health. MacularProte...nd other advanced research. It features a comprehe...d foundation of antioxidants, such as 10 mg of Flo...
Oculair (re-formulated Syntrx Complete) is a potent full-spectrum multiple vitamin/mineral/antioxidant dietary supplement that supports the normal aging process. It is designed to reflect the most re
Ocuvite® vitamin and mineral supplements contain 2 mg of Lutein 8 times more than the leading multivitamins. Ocuvite also contains vitamin antioxidants A, C and E, as well as the minerals zinc,
Most people take their eyes for granted. Like the rest of your body, your eyes need proper nutrition and care to help maintain eye health and vision as you age. In fact, research indicates proper nut
Medicine Products: